Hills Bank & Trust Co. boosted its holdings in Celgene Co. (NASDAQ:CELG) by 7.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,013 shares of the biopharmaceutical company’s stock after acquiring an additional 853 shares during the quarter. Hills Bank & Trust Co.’s holdings in Celgene were worth $1,254,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Skylands Capital LLC increased its stake in Celgene by 93.8% in the 4th quarter. Skylands Capital LLC now owns 80,410 shares of the biopharmaceutical company’s stock worth $8,392,000 after purchasing an additional 38,910 shares in the last quarter. Atria Investments LLC increased its stake in Celgene by 23.5% in the 4th quarter. Atria Investments LLC now owns 32,431 shares of the biopharmaceutical company’s stock worth $3,384,000 after purchasing an additional 6,179 shares in the last quarter. KCS Wealth Advisory purchased a new position in Celgene in the 4th quarter worth about $562,000. Addenda Capital Inc. increased its stake in Celgene by 4.8% in the 4th quarter. Addenda Capital Inc. now owns 57,843 shares of the biopharmaceutical company’s stock worth $6,036,000 after purchasing an additional 2,626 shares in the last quarter. Finally, Hikari Power Ltd increased its stake in Celgene by 25.4% in the 4th quarter. Hikari Power Ltd now owns 71,970 shares of the biopharmaceutical company’s stock worth $7,511,000 after purchasing an additional 14,570 shares in the last quarter. Hedge funds and other institutional investors own 78.10% of the company’s stock.

CELG has been the topic of a number of analyst reports. Royal Bank of Canada dropped their price target on Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a research note on Friday, October 27th. Leerink Swann reissued a “buy” rating and issued a $156.00 price target on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley dropped their price target on Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a research note on Monday, October 23rd. Mizuho reissued a “buy” rating and issued a $128.00 price target on shares of Celgene in a research note on Sunday, February 4th. Finally, SunTrust Banks lowered their target price on Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a research note on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $130.35.

In other news, insider Mark J. Alles purchased 3,260 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average price of $91.90 per share, with a total value of $299,594.00. Following the purchase, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.95% of the company’s stock.

Shares of Celgene Co. (NASDAQ CELG) opened at $91.98 on Wednesday. The company has a market capitalization of $68,831.59, a P/E ratio of 13.34, a P/E/G ratio of 0.64 and a beta of 1.49. Celgene Co. has a 12 month low of $88.32 and a 12 month high of $147.17. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.61 EPS. research analysts expect that Celgene Co. will post 7.68 earnings per share for the current year.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/02/14/hills-bank-trust-co-raises-holdings-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.